Matthew Harer, MD
Position title: Associate Professor
Address:
Division of Neonatology & Newborn Nursery
For Academic Inquiries: (608) 417-6236

Education
BS, University of Wisconsin–Madison, Madison, Wisconsin
MD, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Residency, Pediatrics, University of Wisconsin, Madison, Wisconsin
Fellowship, Neonatology, University of Virginia, Charlottesville, Virginia
Professional Activities
Dr. Matthew W. Harer is associate professor (CHS) in the Division of Neonatology and Newborn Nursery. He is the primary investigator (PI) of the Improving Kidney Outcomes in Neonates into Childhood (IKONIC) research group. Locally, he leads the University of Wisconsin Renal Investigative Neonatal Network (URINN) group that focuses on neonatal kidney issues. Nationally, Harer is the treasurer and sits on the executive committee as well as the board of the Neonatal Kidney Collaborative (NKC). He has served as a research mentor to numerous fellows, residents, medical students and undergraduate students. He has received both teaching and research awards.
Clinical Interests
Harer enjoys taking care of all neonates who require admission to the NICU. He has developed guidelines for babies with prenatally diagnosed hydronephrosis and urinary tract infections, as well as those who require monitoring with near infrared spectroscopy (NIRS).
Research Interests
Harer has nationally recognized expertise in neonatal acute kidney injury. He is the principal investigator of the Harer Research Group, where he performs clinical and translational studies aiming to improve the diagnosis of acute kidney injury. In this area, his group monitors renal oxygenation and is interested in the kidney protective effects of caffeine. Harer has completed a KL2 career development award from ICTR and the NIH as well as an early career Wisconsin Partnership Program award. He is a also a member of the CHNC kidney subgroup and is a part of the ADVANCE study on neonatal AKI. He is leading UW’s participation in the international neonatal AKI study, AWAKEN 2.0.